Wave Lumina’s Post

Thrilled to share that our company Wave Lumina, dedicated to pioneering Contaminant Field Screening Devices (CFSD) for rapid on-site detection of PFAS in environmental samples, has been recognized among the top 64 in the Midwest House Midwest Startup Competition. This journey, at its core, is about collaboration, learning, and pushing the boundaries of environmental science innovation. Being part of such a vibrant community of innovators and thinkers is truly humbling. Our mission to make a tangible difference in environmental health drives us, and this acknowledgment fuels our commitment even more. A heartfelt thank you to our team, especially Joshua Francis and Nathaniel Peck, whose relentless dedication and expertise are the backbone of our progress. To our fellow competitors, we're inspired by your passion and look forward to learning from and with you. Here's to making strides together towards a healthier planet. 🌍 #StartupCompetition #Innovation #EnvironmentalHealth #PFASDetection #Sustainability

How do you feel about dropping pure PFAS directly into you eyes? In 2023, the US FDA approved MIEBO™ (100% perfluorohexyloctane) for topical ophthalmic use as a treatment of the signs and symptoms of dry eye disease. My back of the envelope calculations estimate a dosage of 0.5 grams per day based on the prescribing information. In 2023, the US EPA proposed health-based Maximum Containment Level Goals of “Zero” for PFOA and PFOS, two specific types of per- and polyfluoroalkyl substances (PFAS), often referred to as ‘Forever Chemicals’. Practically, the drinking water levels that will be enforced for these compounds is 4.0 parts per trillion (ng/L). MIEBO™ is a PFAS. The characteristic carbon-fluorine bond (C-F) of polyfluoroalkyl substances like MIEBO™ and other PFOA gives them exceptional functionality, but it is also cause for health and environmental concern. According to the prescribing information from MIEBO™ manufacturer (Bausch & Lomb Incorporated or its affiliates), “The pharmacokinetics of perfluorohexyloctane following topical ocular administration of MIEBO has not been quantitatively characterized in humans. A single pharmacokinetic (PK) study was conducted that showed low systemic perfluorohexyloctane blood levels after topical ocular administration. Perfluorohexyloctane was not metabolized by human liver microsomes in vitro.” Do you believe MIEBO™ is 35 million times safer than other PFAS? If MIEBO™ is not metabolized, is it eliminated and if so, where does it go? Please share your thoughts (and check my maths)! 🤔